Traore Lassina, Nikiema Ouéogo, Ouattara Abdoul Karim, Compaore Tegwindé Rébéca, Soubeiga Serge Théophile, Diarra Birama, Obiri-Yeboah Dorcas, Sorgho Pegdwendé Abel, Djigma Florencia Wendkuuni, Bisseye Cyrille, Yonli Albert Théophane, Simpore Jacques
Biomolecular Research Center Pietro Annigoni (CERBA).
LABIOGENE UFR/SVT, University Ouaga I Prof. Joseph KI-ZERBO 01 BP 364 Ouagadougou, Burkina Faso.
Mediterr J Hematol Infect Dis. 2017 Sep 1;9(1):e2017049. doi: 10.4084/MJHID.2017.049. eCollection 2017.
Epstein Barr Virus (EBV) and Human Herpes Virus 6 (HHV-6) are responsible for severe diseases, particularly in immunocompromised persons. There is limited data of the infection of these opportunistic viruses in Burkina Faso. The purpose of this study was to characterize EBV and HHV-6 subtypes and to assess their impact on CD4 T cell count, HIV-1 viral load and antiretroviral treatment in people living with HIV-1. The study population consisted of 238 HIV-positive patients with information on the CD4 T cell count, HIV-1 viral load and HAART. Venous blood samples collected in EDTA tubes were used for EBV and HHV-6 Real Time PCR subtyping. An infection rate of 6.7% (16/238) and 7.1% (17/238) were found respectively for EBV and HHV-6 in the present study. Among EBV infections, similar prevalence was noted for both subtypes (3.9% (9/238) for EBV-1 vs 4.6% (11/238) for EBV-2) with 2.1% (5/238) of co-infection. HHV-6A infection represented 6.3% (15/238) of the study population against 5.0% (12/238) for HHV-6B. EBV-2 infection was significantly higher in patients with CD4 T cell count ≥ 500 compared to those with CD4 T cell count less than 500 cells (1.65% vs 8.56%, p = 0,011). The prevalence of EBV and HHV-6 infections was almost similar in HAART-naive and HAART-experienced patients. The present study provides information on the prevalence of EBV and HHV-6 subtypes in people living with HIV-1 in Burkina Faso. The study also suggests that HAART treatment has no effect on infection with these opportunistic viruses in people living with HIV-1.
爱泼斯坦-巴尔病毒(EBV)和人类疱疹病毒6型(HHV-6)可引发严重疾病,尤其是在免疫功能低下者中。布基纳法索关于这些机会性病毒感染的数据有限。本研究的目的是对EBV和HHV-6亚型进行特征分析,并评估它们对HIV-1感染者的CD4 T细胞计数、HIV-1病毒载量和抗逆转录病毒治疗的影响。研究人群包括238名HIV阳性患者,他们有关于CD4 T细胞计数、HIV-1病毒载量和高效抗逆转录病毒治疗(HAART)的信息。采集于乙二胺四乙酸(EDTA)管中的静脉血样本用于EBV和HHV-6的实时聚合酶链反应(PCR)亚型分析。在本研究中,EBV和HHV-6的感染率分别为6.7%(16/238)和7.1%(17/238)。在EBV感染中,两种亚型的患病率相似(EBV-1为3.9%(9/238),EBV-2为4.6%(11/238)),合并感染率为2.1%(5/238)。HHV-6A感染占研究人群的6.3%(15/238),而HHV-6B为5.0%(12/238)。与CD4 T细胞计数低于500个细胞的患者相比,CD4 T细胞计数≥500的患者中EBV-2感染显著更高(1.65%对8.56%,p = 0.011)。在未接受过HAART和接受过HAART治疗的患者中EBV和HHV-6感染的患病率几乎相似。本研究提供了布基纳法索HIV-1感染者中EBV和HHV-6亚型患病率的信息。该研究还表明,HAART治疗对HIV-1感染者感染这些机会性病毒没有影响。